hnRNP A2B1 as a promising therapeutic target for radiomodulatory drug development: evidence from computational and experimental studies.

Front Pharmacol · 2025 · PMC13006754 · PMID 41878057

Europe PMC DOI

hedged sentence

0.0000

closest p · 0.0× alpha

0.0000

boldest claim

The sentences

highly significantp = 1.7 × 10 −7actually significant

One-way ANOVA confirmed highly significant differences across doses (F(5,12) = 47.4, p = 1.7 × 10 −7 ), with Tukey’s HSD post-hoc tests revealing robust separation from 2 Gy onward.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.